AstraZeneca PLC (AZN)vsDocGo Inc (DCGO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
DCGO
DocGo Inc
$0.71
-0.20%
HEALTHCARE · Cap: $70.92M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 18131% more annual revenue ($58.74B vs $322.20M). AZN leads profitability with a 17.4% profit margin vs -56.6%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DCGO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for DCGO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -89.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : DCGO
The primary concerns for DCGO are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while DCGO is a turnaround play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.98 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a forward-thinking mobile healthcare service provider that transforms patient access through its cutting-edge logistics and telehealth platform. Focusing on urgent care, diagnostic testing, and health screenings, the company not only improves patient experiences but also optimizes healthcare delivery across various settings. With its robust technological advancements and dedication to expanding healthcare access, DocGo stands out as a compelling investment opportunity in the fast-growing healthtech landscape, appealing to institutional investors seeking growth potential.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?